XBiotech (XBIT) Operating Income (2014 - 2026)
XBiotech (XBIT) posted quarterly Operating Income of -$29.8 million for Q4 2025, down 240.13% year-over-year from $21.2 million in Q4 2024, and down 392.06% quarter-over-quarter from -$6.0 million in Q3 2025.
XBiotech (XBIT) Operating Income (2014 - 2026) Analysis & Trends
XBiotech's Operating Income history runs 12 years deep, the most recent figure standing at -$29.8 million for Q4 2025.
- In Q4 2025, Operating Income fell 240.13% year-over-year to -$29.8 million; the TTM figure through Dec 2025 stood at -$55.7 million (down 31.12% YoY), while the FY2025 annual figure was -$55.7 million, down 31.11% from the prior year.
- Operating Income for Q4 2025 stood at -$29.8 million, down from -$6.0 million in the prior quarter.
- The five-year high for Operating Income was -$3.6 million in Q1 2021, with the low at -$29.8 million in Q4 2025.
- The 5-year median for Operating Income is -$8.3 million (2022), against an average of -$9.8 million.
- Peak annual rise in Operating Income reached 57.66% in 2025, while the deepest fall reached 240.13% in 2025.
- XBiotech's Operating Income stood at -$7.2 million in 2021, then declined by 13.47% to -$8.2 million in 2022, then declined by 5.22% to -$8.6 million in 2023, then retreated by 1.86% to -$8.7 million in 2024, then plunged by 240.13% to -$29.8 million in 2025.
- Business Quant data shows XBIT's Operating Income at -$29.8 million in Q4 2025, -$6.0 million in Q3 2025, and -$6.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | -6.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.15 Mn |
| Dec 31, 2025 | -29.76 Mn |
| Sep 30, 2025 | -6.05 Mn |
| Jun 30, 2025 | -6.34 Mn |
| Mar 31, 2025 | -13.55 Mn |
| Dec 31, 2024 | -8.75 Mn |
| Sep 30, 2024 | -7.90 Mn |
| Jun 30, 2024 | -14.97 Mn |
| Mar 31, 2024 | -10.85 Mn |
| Dec 31, 2023 | -8.59 Mn |
| Sep 30, 2023 | -8.52 Mn |
| Jun 30, 2023 | -13.26 Mn |
| Mar 31, 2023 | -7.15 Mn |
| Dec 31, 2022 | -8.16 Mn |
| Sep 30, 2022 | -6.39 Mn |
| Jun 30, 2022 | -12.09 Mn |
| Mar 31, 2022 | -7.85 Mn |
| Dec 31, 2021 | -7.19 Mn |
| Sep 30, 2021 | -3.73 Mn |
| Jun 30, 2021 | -10.61 Mn |